CD274 and neoplasm: Pembrolizumab, in combination with the first-line chemotherapy for patients with mTNBC and a PD-L1 positive tumor (CPS ≥ 10), has also achieved FDA and EMA approval and is recommended in the ESMO guidelines as the first-line treatment in mTNBC with CPS ≥ 10 [5, 62, 63].